

## COVER LETTER - RESUBMISSION

Dear Editor,

Please find enclosed the revised manuscript (number 18352) titled "How to predict clinical relapse in inflammatory bowel disease patients."

Authors: Elisa Liverani, Eleonore Scaioli, Richard John Digby\*, Matteo Bellanova, Andrea Belluzzi.

Department of Medical and Surgical Sciences, University of Bologna, Bologna, 40138 Italy.

\*Department of Physiology, development and Neuroscience, University of Cambridge, Cambridge CB2 3EG, UK.

We re-submit our paper to your consideration for publication after revision, according to the points raised by the reviewers:

- as regards genetic and serologic markers, they have been discussed more extensively, as suggested by reviewers.
- As regards stool biomarkers, Indium 111-labeled leukocytes, alpha1-antitrypsin, alpha2-macroglobulin, myeloperoxidase, PMN-elastase have only been cited in this review, as we have insufficient data about their utility in the prediction of clinical relapse so far. We prefer focus the attention of the reader on more promising fecal markers, such as calprotectin, lactoferrin and S100A12.
- The manuscript has been modified according to the editor's suggestion indicated in the Edited Manuscript File. All the revisions made are highlighted in the updated version.
- References have been checked, PMID and DOI have been added where missing.
- We have revised the manuscript according to the Guidelines and Requirements for manuscript revision- Topic Highlight.
- An audio core tip has been provided.
- Language has been reviewed by one of the author (Richard John Digby, MD) Native Speakers of English.
- You can find the "Copyright Assignment" attached.

The content of the manuscript is original and it has not been published or accepted for publication, either in whole or in part, in any form.

Bologna, July 7, 2015

Best regards,

Andrea Belluzzi, MD